Title:
HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION
Document Type and Number:
WIPO Patent Application WO/2021/153635
Kind Code:
A1
Abstract:
The present invention provides a non-lamellar liquid crystal forming composition which is highly safe. The present invention relates to a non-lamellar liquid crystal forming composition that includes an amphipathic compound represented by general formula (I) and phospholipid, and that has improved biocompatibility because of the phospholipid. In the formula, X and Y are each a hydrogen bond or are combined to represent an oxygen atom, n is 1 or 2, m is 1 or 2, and R is a hydrophilic group having one or more hydroxyl groups.
Inventors:
TABATA YASUHIKO (JP)
MURAKAMI TAKAHIDE (JP)
TODO HIROAKI (JP)
ITAKURA SHOKO (JP)
SUGIBAYASHI KENJI (JP)
HIJIKURO ICHIRO (JP)
TANOMURA MASAHISA (JP)
MURAKAMI TAKAHIDE (JP)
TODO HIROAKI (JP)
ITAKURA SHOKO (JP)
SUGIBAYASHI KENJI (JP)
HIJIKURO ICHIRO (JP)
TANOMURA MASAHISA (JP)
Application Number:
PCT/JP2021/002917
Publication Date:
August 05, 2021
Filing Date:
January 27, 2021
Export Citation:
Assignee:
FARNEX INCORPORATED (JP)
International Classes:
A61K47/24; A61K9/08; A61K9/107; A61K9/12; A61K38/08; A61K45/00; A61K47/14; A61K47/69; A61P5/06; A61P35/00; A61P41/00; C07C69/003; C07D307/20; C07D493/04
Domestic Patent References:
| WO2011078383A1 | 2011-06-30 | |||
| WO2014178256A1 | 2014-11-06 | |||
| WO2006043705A1 | 2006-04-27 | |||
| WO2011078383A1 | 2011-06-30 | |||
| WO2014178256A1 | 2014-11-06 |
Foreign References:
| JP2004059470A | 2004-02-26 | |||
| JP2012502922A | 2012-02-02 | |||
| JP2019099478A | 2019-06-24 | |||
| JP2020011237A | 2020-01-23 | |||
| JP2020211758A | 2020-12-21 |
Other References:
OKADA, A. ET AL.: "Controlled release of a model hydrophilic high molecular weight compound from injectable non-lamellar liquid crystal formulations containing different types of phospholipids", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 577, no. 118944, 21 December 2019 (2019-12-21), pages 1 - 9, XP086066921, [retrieved on 20200000], DOI: https://doi.org/10.1016/j- ijpharm.2019.118944
AKIE OKADA, SHOKO ITAKURA, HIROAKI TODO, ICHIRO HIJIKURO, KENJI SUGIBAYASHI: "[26P-pm165S] Development of depot formulations using non-lamellar liquid crystalline lipids", 25 March 2020 (2020-03-25), pages 1 - 1, XP055956426, Retrieved from the Internet
OKADA, AKIE; ITAKURA, SHOKO; TODO, HIROAKI; HIJIKURO, ICHIRO; SUGIBAYASHI, KENJI: "1-4-22 Development of depot formulations based on non-lamellar liquid crystalline forming lipids", LECTURE ABSTRACTS OF THE 35TH ANNUAL MEETING OF THE ACADEMY OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY; MAY 14-16, 2020, vol. 35, 8 May 2020 (2020-05-08), Japan, pages 130, XP009538730
AKIE OKADA, SHOKO ITAKURA, HIROAKI TODO, ICHIRO TSUCHIGURO, KENJI SUGIBAYASHI: "P-55 Preparation of non-lamellar liquid crystalline formulations that enable control of middle- molecule drug release", PROGRAM PREPRINTS OF THE 36TH ANNUAL MEETING OF THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM; AUGUST 28-29, 2020, vol. 36, 10 August 2020 (2020-08-10) - 29 August 2020 (2020-08-29), JP, pages 192, XP009538728
SHIRAISHI, MORIHIRO : "P-67 Effect of phospholipid addition on FD-4 release from phospholipid mixture of non-lamellar liquid crystalline", PROGRAM PREPRINTS OF THE 36TH ANNUAL MEETING OF THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM (DDS); JULY 4-5, 2019, vol. 36, 15 June 2019 (2019-06-15) - 5 July 2019 (2019-07-05), JP, pages 192, XP009538729
HINTON T.M. ET AL., TOXICOLOGY RESEARCH, vol. 3, 2014, pages 11 - 22
WIBROE P.P. ET AL.: "Nanomedicine: Nanotechnology", BIOLOGY AND MEDICINE, vol. 11, 2015, pages 1909 - 1914
See also references of EP 4098281A4
AKIE OKADA, SHOKO ITAKURA, HIROAKI TODO, ICHIRO HIJIKURO, KENJI SUGIBAYASHI: "[26P-pm165S] Development of depot formulations using non-lamellar liquid crystalline lipids", 25 March 2020 (2020-03-25), pages 1 - 1, XP055956426, Retrieved from the Internet
OKADA, AKIE; ITAKURA, SHOKO; TODO, HIROAKI; HIJIKURO, ICHIRO; SUGIBAYASHI, KENJI: "1-4-22 Development of depot formulations based on non-lamellar liquid crystalline forming lipids", LECTURE ABSTRACTS OF THE 35TH ANNUAL MEETING OF THE ACADEMY OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY; MAY 14-16, 2020, vol. 35, 8 May 2020 (2020-05-08), Japan, pages 130, XP009538730
AKIE OKADA, SHOKO ITAKURA, HIROAKI TODO, ICHIRO TSUCHIGURO, KENJI SUGIBAYASHI: "P-55 Preparation of non-lamellar liquid crystalline formulations that enable control of middle- molecule drug release", PROGRAM PREPRINTS OF THE 36TH ANNUAL MEETING OF THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM; AUGUST 28-29, 2020, vol. 36, 10 August 2020 (2020-08-10) - 29 August 2020 (2020-08-29), JP, pages 192, XP009538728
SHIRAISHI, MORIHIRO : "P-67 Effect of phospholipid addition on FD-4 release from phospholipid mixture of non-lamellar liquid crystalline", PROGRAM PREPRINTS OF THE 36TH ANNUAL MEETING OF THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM (DDS); JULY 4-5, 2019, vol. 36, 15 June 2019 (2019-06-15) - 5 July 2019 (2019-07-05), JP, pages 192, XP009538729
HINTON T.M. ET AL., TOXICOLOGY RESEARCH, vol. 3, 2014, pages 11 - 22
WIBROE P.P. ET AL.: "Nanomedicine: Nanotechnology", BIOLOGY AND MEDICINE, vol. 11, 2015, pages 1909 - 1914
See also references of EP 4098281A4
Attorney, Agent or Firm:
HIRAKI & ASSOCIATES (JP)
Download PDF: